In the 192 patients who had available tumor tissue, no differences were found regarding the efficacy of nivolumab compared to that of placebo in patients’ OS.27,36 In CHECKMATE-032, the benefits of nivolumab or the combinations of nivolumab with ipilimumab were observed, no matter the immunohistochemical status of PD-L1 independently.31 Finally, in the JAVELIN Gastric 300 that used the PD-L1 IHC 73-10 pharmDx assay, no differences were identified in the outcomes of avelumab treatment between patients with PD-L1-positive or -negative tumors. Here, CD274 is linked to neoplasm.